FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

Phase 1CYWC628Positive

AI Analysis

Summary

FibroBiologics has completed manufacturing of the third batch of CYWC628 drug product for its Phase 1/2 clinical trial in diabetic foot ulcers. This is a routine manufacturing milestone update.

Clinical Trial Data

Phase

Phase 1/2

Importance:3/10

Sentiment:

0.30

manufacturingclinical_trialdiabetic_foot_ulcerdrug_product

Related Companies

$FBLG

Read the original article

Published by yahoo_finance on July 7, 2026 12:30 PM

Read Original